At the forefront of epidemiological research, Dr. Acharya's investigations into the prevalence and risk factors associated with ocular inflammatory conditions have shed invaluable light on these complex diseases, guiding clinical practice and public health initiatives alike. As Principal Investigator of the NIH-funded First-line Antimetabolites for Steroid-Sparing Treatment (FAST) Trial, she leads a multidisciplinary team in a groundbreaking endeavor to redefine the standard of care for uveitis patients nationwide.

Not content with mere innovation, Dr. Acharya is also instrumental in driving standardization efforts within the field, serving as a key figure in the Standardization of Uveitis Nomenclature working group. Her leadership role in the Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial underscores her unwavering commitment to rigorous scientific inquiry and evidence-based practice.

Beyond her scholarly pursuits, Dr. Acharya's influence extends to the highest echelons of professional societies, where she plays an integral role in shaping the future of ophthalmology. As a member of the executive committee of the American Uveitis Society and chair of the American Academy of Ophthalmology Knowledge Base Panel for Uveitis, she champions the dissemination of knowledge and best practices, ensuring that practitioners across the nation are equipped to deliver the highest standard of care to their patients.

01:26:49

Fork in the Road: Deciding Which Uveitis Treatment is Best

FEB 13, 2024 by Christopher R Henry, MD, Ghazala A Datoo O'Keefe, Edmund Tsui, Nisha Acharya, Douglas A Jabs, MBA, Parisa Emami Naeini, Shilpa Kodati, Arjun B Sood

In this webinar, Drs. Acharya, Emami, Henry, Jabs, Kodati, O'Keefe, Sood, and Tsui, provide cases centered around four of the latest uveitis-related clinical... 

Presentations / Presentation

In the landscape of ophthalmology and epidemiology, Dr. Nisha Acharya stands as a beacon of excellence, renowned for her profound expertise and tireless dedication to advancing the understanding and treatment of ocular inflammatory diseases. Holding the distinguished Elizabeth C. Proctor Professorship at the University of California San Francisco, Dr. Acharya's contributions extend far beyond the confines of academia, profoundly impacting the lives of countless individuals afflicted by uveitis and related conditions.

With a clinical focus centered on uveitis and ocular inflammatory diseases, Dr. Acharya exemplifies the epitome of specialized care, offering patients not only expert diagnosis and treatment but also a compassionate understanding of the challenges they face. Her commitment to excellence is evident in every aspect of her work, from pioneering research endeavors to leading-edge clinical trials aimed at evaluating the efficacy of novel treatment modalities.